胶质母细胞瘤患者预后外周血游离DNA水平与中性粒细胞介导的NETosis之间的皮质类固醇依赖性关联。

IF 10 1区 医学 Q1 ONCOLOGY
Jacob E Till, Nicholas J Seewald, Zachariya Yazdani, Zhuoyang Wang, Dominique Ballinger, Heather Samberg, Siri Dandu, Camilla Macia, Melinda Yin, Aseel Abdalla, Timothy Prior, Shivani S Shah, Thara Patel, Emily McCoy, Maikel Mansour, Carson A Wills, Veronica Bochenek, Jonathan Serrano, Matija Snuderl, Richard E Phillips, Donald M O'Rourke, Nduka M Amankulor, Ali Nabavizadeh, Arati S Desai, Kandace Gollomp, Zev A Binder, Wanding Zhou, Stephen J Bagley, Erica L Carpenter
{"title":"胶质母细胞瘤患者预后外周血游离DNA水平与中性粒细胞介导的NETosis之间的皮质类固醇依赖性关联。","authors":"Jacob E Till, Nicholas J Seewald, Zachariya Yazdani, Zhuoyang Wang, Dominique Ballinger, Heather Samberg, Siri Dandu, Camilla Macia, Melinda Yin, Aseel Abdalla, Timothy Prior, Shivani S Shah, Thara Patel, Emily McCoy, Maikel Mansour, Carson A Wills, Veronica Bochenek, Jonathan Serrano, Matija Snuderl, Richard E Phillips, Donald M O'Rourke, Nduka M Amankulor, Ali Nabavizadeh, Arati S Desai, Kandace Gollomp, Zev A Binder, Wanding Zhou, Stephen J Bagley, Erica L Carpenter","doi":"10.1158/1078-0432.CCR-24-3169","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Noninvasive prognostic biomarkers to inform clinical decision-making are an urgent unmet need for the management of patients with glioblastoma (GBM). We previously showed that higher circulating cell-free DNA (ccfDNA) concentration is associated with worse survival in GBM. However, the biology underlying this is unknown.</p><p><strong>Experimental design: </strong>We prospectively enrolled 129 patients with treatment-naïve GBM with blood drawn prior to initial resection (baseline) and at the time of the first postradiotherapy MRI. We performed ccfDNA methylation deconvolution to determine cellular sources of ccfDNA. ELISA was performed to detect citrullinated histone 3 (citH3), a marker of neutrophil extracellular traps (NET). Multiplex proteomic analysis was used to measure soluble inflammatory proteins.</p><p><strong>Results: </strong>We found that neutrophils contributed the highest proportion of prognostic ccfDNA. The percentage of ccfDNA derived from neutrophils was correlated with total [ccfDNA] but only in patients receiving preoperative corticosteroids. At baseline and on therapy, [citH3] was significantly higher in the plasma of patients with GBM receiving corticosteroids compared with corticosteroid-naïve GBM or no-cancer controls. Unsupervised hierarchical clustering of ccfDNA methylation patterns yielded two clusters, with one enriched for patients with the NETosis phenotype and who received corticosteroids. Unsupervised clustering of circulating inflammatory proteins yielded similar results.</p><p><strong>Conclusions: </strong>These data suggest neutrophil-mediated NETosis is the dominant source of prognostic ccfDNA in patients with GBM and may be associated with glucocorticoid exposure. If further studies show that pharmacological inhibition of NETosis can mitigate the deleterious effects of corticosteroids, these plasma markers will have important clinical utility as noninvasive correlative biomarkers.</p>","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":" ","pages":"1292-1304"},"PeriodicalIF":10.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961315/pdf/","citationCount":"0","resultStr":"{\"title\":\"Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma.\",\"authors\":\"Jacob E Till, Nicholas J Seewald, Zachariya Yazdani, Zhuoyang Wang, Dominique Ballinger, Heather Samberg, Siri Dandu, Camilla Macia, Melinda Yin, Aseel Abdalla, Timothy Prior, Shivani S Shah, Thara Patel, Emily McCoy, Maikel Mansour, Carson A Wills, Veronica Bochenek, Jonathan Serrano, Matija Snuderl, Richard E Phillips, Donald M O'Rourke, Nduka M Amankulor, Ali Nabavizadeh, Arati S Desai, Kandace Gollomp, Zev A Binder, Wanding Zhou, Stephen J Bagley, Erica L Carpenter\",\"doi\":\"10.1158/1078-0432.CCR-24-3169\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Noninvasive prognostic biomarkers to inform clinical decision-making are an urgent unmet need for the management of patients with glioblastoma (GBM). We previously showed that higher circulating cell-free DNA (ccfDNA) concentration is associated with worse survival in GBM. However, the biology underlying this is unknown.</p><p><strong>Experimental design: </strong>We prospectively enrolled 129 patients with treatment-naïve GBM with blood drawn prior to initial resection (baseline) and at the time of the first postradiotherapy MRI. We performed ccfDNA methylation deconvolution to determine cellular sources of ccfDNA. ELISA was performed to detect citrullinated histone 3 (citH3), a marker of neutrophil extracellular traps (NET). Multiplex proteomic analysis was used to measure soluble inflammatory proteins.</p><p><strong>Results: </strong>We found that neutrophils contributed the highest proportion of prognostic ccfDNA. The percentage of ccfDNA derived from neutrophils was correlated with total [ccfDNA] but only in patients receiving preoperative corticosteroids. At baseline and on therapy, [citH3] was significantly higher in the plasma of patients with GBM receiving corticosteroids compared with corticosteroid-naïve GBM or no-cancer controls. Unsupervised hierarchical clustering of ccfDNA methylation patterns yielded two clusters, with one enriched for patients with the NETosis phenotype and who received corticosteroids. Unsupervised clustering of circulating inflammatory proteins yielded similar results.</p><p><strong>Conclusions: </strong>These data suggest neutrophil-mediated NETosis is the dominant source of prognostic ccfDNA in patients with GBM and may be associated with glucocorticoid exposure. If further studies show that pharmacological inhibition of NETosis can mitigate the deleterious effects of corticosteroids, these plasma markers will have important clinical utility as noninvasive correlative biomarkers.</p>\",\"PeriodicalId\":10279,\"journal\":{\"name\":\"Clinical Cancer Research\",\"volume\":\" \",\"pages\":\"1292-1304\"},\"PeriodicalIF\":10.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961315/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/1078-0432.CCR-24-3169\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1078-0432.CCR-24-3169","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:为临床决策提供无创预后生物标志物是胶质母细胞瘤(GBM)患者治疗的迫切需求。我们之前的研究表明,较高的循环游离细胞DNA浓度(ccfDNA)与GBM患者较差的生存率相关。然而,这背后的生物学原理尚不清楚。实验设计:我们前瞻性地招募了129例treatment-naïve GBM患者,在初始切除(基线)之前和放疗后第一次MRI时抽血。我们进行了ccfDNA甲基化反褶积来确定ccfDNA的细胞来源。采用ELISA法检测中性粒细胞胞外陷阱(NETs)标志物瓜氨酸化H3 (citH3)。多重蛋白质组学分析用于测定可溶性炎症蛋白。结果:我们发现中性粒细胞对预后ccfDNA的贡献比例最高。来源于中性粒细胞的ccfDNA百分比与总ccfDNA相关,但仅适用于术前接受皮质类固醇治疗的患者。在基线和治疗期间,与corticosteroid-naïve GBMs或无癌对照相比,接受皮质类固醇治疗的GBM患者血浆中的[citH3]明显较高。ccfDNA甲基化模式的无监督分层聚类产生两个聚类,其中一个富集于NETosis表型和接受皮质类固醇治疗的患者。循环炎症蛋白的无监督聚类也产生了类似的结果。结论:这些数据表明中性粒细胞介导的NETosis是GBM患者预后ccfDNA的主要来源,并可能与糖皮质激素暴露有关。如果进一步的研究表明药物抑制NETosis可以减轻皮质类固醇的有害作用,这些血浆标志物将作为非侵入性相关生物标志物具有重要的临床应用价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma.

Purpose: Noninvasive prognostic biomarkers to inform clinical decision-making are an urgent unmet need for the management of patients with glioblastoma (GBM). We previously showed that higher circulating cell-free DNA (ccfDNA) concentration is associated with worse survival in GBM. However, the biology underlying this is unknown.

Experimental design: We prospectively enrolled 129 patients with treatment-naïve GBM with blood drawn prior to initial resection (baseline) and at the time of the first postradiotherapy MRI. We performed ccfDNA methylation deconvolution to determine cellular sources of ccfDNA. ELISA was performed to detect citrullinated histone 3 (citH3), a marker of neutrophil extracellular traps (NET). Multiplex proteomic analysis was used to measure soluble inflammatory proteins.

Results: We found that neutrophils contributed the highest proportion of prognostic ccfDNA. The percentage of ccfDNA derived from neutrophils was correlated with total [ccfDNA] but only in patients receiving preoperative corticosteroids. At baseline and on therapy, [citH3] was significantly higher in the plasma of patients with GBM receiving corticosteroids compared with corticosteroid-naïve GBM or no-cancer controls. Unsupervised hierarchical clustering of ccfDNA methylation patterns yielded two clusters, with one enriched for patients with the NETosis phenotype and who received corticosteroids. Unsupervised clustering of circulating inflammatory proteins yielded similar results.

Conclusions: These data suggest neutrophil-mediated NETosis is the dominant source of prognostic ccfDNA in patients with GBM and may be associated with glucocorticoid exposure. If further studies show that pharmacological inhibition of NETosis can mitigate the deleterious effects of corticosteroids, these plasma markers will have important clinical utility as noninvasive correlative biomarkers.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Cancer Research
Clinical Cancer Research 医学-肿瘤学
CiteScore
20.10
自引率
1.70%
发文量
1207
审稿时长
2.1 months
期刊介绍: Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信